Long Term Clinical Toxicity of Radiation Therapy in Prostate Cancer Patients with Inflammatory Bowel Disease

Overview

Journal Rep Pract Oncol Radiother

Specialty Oncology

Date 2016 Dec 7

PMID 27920612

Citations 11

Authors

Matthew M Gestaut

Gregory P Swanson

Affiliations

Soon will be listed here.

Abstract

Aim: The study's aim was to examine the clinical impact of radiation therapy (RT) on GI toxicity in Inflammatory Bowel Disease (IBD) patients.

Background: IBD has long been considered a risk factor for increased bowel toxicity from RT; however, minimal evidence exists on patients with prostate cancer (PC) and IBD.

Materials And Methods: The tumor registry was queried for patients with IBD and PC from the years 1990-2013. A retrospective review was conducted for patients who received RT. Radiation treatment and toxicity data were collected.

Results: Average length of follow-up was 12 years (median 9.54, range 0.42-19.9). The majority had well controlled baseline bowel function on medical management. Prior to radiation, 60% of patients (9/15) and 40% (6/15) reported grade 0 (G0) and grade (G1) diarrhea at baseline, respectively. No baseline proctitis existed. Following radiation treatment, 78% (14/18) of patients experienced G0 diarrhea while 22% (4/18) reported G1 diarrhea. No patients suffered from greater than G1 diarrhea. Sixty-six percent (12/18), 17% (3/18) and 17% (3/18) of patients experienced G0, G1, and G2 proctitis, respectively. No patients suffered post-radiation stricture formation, and all patients with G2 proctitis received 3dCRT.

Conclusions: Limited published data is available exploring RT for patients with PC and IBD. This analysis offers valuable insight into appropriate counseling for a rare patient subset. Radiation improved late G1 diarrhea rates. Grade 2 proctitis was only encountered in 3dCRT patients. No post-radiation complications occurred. Our findings suggest that IBD patients experience minimal toxicity in the era of IMRT based RT.

Citing Articles

Rectal Cancer and Radiation in Colitis.

Lynn P, Cronin C, Rangarajan S, Widmar M Clin Colon Rectal Surg. 2024; 37(1):30-36.

PMID: 38188064 PMC: 10769583. DOI: 10.1055/s-0043-1762561.

The Utility of Salvage Radiotherapy for an Inoperable Inguinal Recurrence of Squamous Cell Carcinoma of the Penis.

Janes W, Johnston P, Organ M, Thoms J, Gaviolli E Cureus. 2023; 15(11):e48815.

PMID: 38106763 PMC: 10722349. DOI: 10.7759/cureus.48815.

Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review.

Trotta M, Patel K, Singh S, Verma V, Ryckman J Pract Radiat Oncol. 2023; 13(5):454-465.

PMID: 37100389 PMC: 10527639. DOI: 10.1016/j.prro.2023.04.006.

Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review.

Bodofsky S, Freeman R, Hong S, Chundury A, Hathout L, Deek M J Gastrointest Oncol. 2022; 13(5):2565-2582.

PMID: 36388654 PMC: 9660071. DOI: 10.21037/jgo-22-138.

Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.

Lischalk J, Blacksburg S, Mendez C, Repka M, Sanchez A, Carpenter T Radiat Oncol. 2021; 16(1):126.

PMID: 34243797 PMC: 8267228. DOI: 10.1186/s13014-021-01850-1.

References

Schofield P, Holden D, Carr N . Bowel disease after radiotherapy. J R Soc Med. 1983; 76(6):463-6. PMC: 1439199. DOI: 10.1177/014107688307600606. View

Tiersten A, Saltz L . Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. J Clin Oncol. 1996; 14(7):2043-6. DOI: 10.1200/JCO.1996.14.7.2043. View

Pohl C, Hombach A, Kruis W . Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000; 47(31):57-70. View

DAmico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969-74. DOI: 10.1001/jama.280.11.969. View

Trott K, Kamprad F . Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother Oncol. 1999; 51(3):197-203. DOI: 10.1016/s0167-8140(99)00066-3. View

Zietman A, Bae K, Slater J, Shipley W, Efstathiou J, Coen J . Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010; 28(7):1106-11. PMC: 2834463. DOI: 10.1200/JCO.2009.25.8475. View

Song D, Lawrie W, Abrams R, Kafonek D, Bayless T, Welsh J . Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001; 51(2):455-9. DOI: 10.1016/s0360-3016(01)01629-7. View

Becker-Schiebe M, Abaci A, Ahmad T, Hoffmann W . Reducing radiation-associated toxicity using online image guidance (IGRT) in prostate cancer patients undergoing dose-escalated radiation therapy. Rep Pract Oncol Radiother. 2016; 21(3):188-94. PMC: 5002020. DOI: 10.1016/j.rpor.2016.01.005. View

Lengua R, Gonzalez M, Barahona K, Ixquiac M, Lucero J, Montenegro E . Toxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer. Rep Pract Oncol Radiother. 2014; 19(4):234-8. PMC: 4104014. DOI: 10.1016/j.rpor.2013.09.007. View

10.

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1785-94. DOI: 10.1053/j.gastro.2011.01.055. View

11.

LOVE J, Irvine E, Fedorak R . Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992; 14(1):15-9. DOI: 10.1097/00004836-199201000-00005. View

12.

Fuentes-Raspall R, Inoriza J, Rosello-Serrano A, Aunon-Sanz C, Garcia-Martin P, Oliu-Isern G . Late rectal and bladder toxicity following radiation therapy for prostate cancer: Predictive factors and treatment results. Rep Pract Oncol Radiother. 2014; 18(5):298-303. PMC: 3863251. DOI: 10.1016/j.rpor.2013.05.006. View

13.

Zelefsky M, Fuks Z, Hunt M, Yamada Y, Marion C, Ling C . High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53(5):1111-6. DOI: 10.1016/s0360-3016(02)02857-2. View

14.

Roedel F, Kley N, Beuscher H, Hildebrandt G, Keilholz L, Kern P . Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion. Int J Radiat Biol. 2002; 78(8):711-9. DOI: 10.1080/09553000210137671. View

15.

Murphy C, Heller S, Ruth K, Buyyounouski M, Weinberg D, Uzzo R . Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Pract Radiat Oncol. 2014; 5(3):e215-e222. DOI: 10.1016/j.prro.2014.09.004. View

16.

Faubion Jr W, Loftus Jr E, Harmsen W, Zinsmeister A, Sandborn W . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121(2):255-60. DOI: 10.1053/gast.2001.26279. View

17.

Pai H, Keyes M, Morris W, Christie J . Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. Brachytherapy. 2012; 12(2):126-33. DOI: 10.1016/j.brachy.2012.04.008. View

18.

Bernstein C, Blanchard J, Kliewer E, Wajda A . Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91(4):854-62. DOI: 10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z. View

19.

. Prostate cancer. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009; 2(3):224-48. DOI: 10.6004/jnccn.2004.0021. View

20.

Loftus Jr E, Sandborn W . Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31(1):1-20. DOI: 10.1016/s0889-8553(01)00002-4. View